Login Register Cart 0
Mini-Review Article

Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review

Author(s): Jingwen Li, Xinyi Wang, Na Li , Ying Jiang, Heqing Huang*, Tao Wang, Zhicheng Lin and Nian Xiong*

Volume 20, Issue 4, 2020

Page: [285 - 288] Pages: 4

DOI: 10.2174/1566523220999200820172829

open access plus

conference banner
Abstract

Patients infected with SARS-CoV-2 carry the coronavirus disease 2019 (COVID-19) which involves multiple systems and organs with acute respiratory distress syndrome (ARDS) as the most common complication, largely due to cytokine storms or dysregulated immunity. As such, there are many severe patients with complications such as cytokine storm syndrome (CSS), who have a high fatality rate. Neither specific anti-SARS-CoV-2 drugs nor vaccines exist currently. Current treatment relies mainly on self-recovery through patients' immune function. Mesenchymal stem cells (MSCs) is a kind of multipotent tissue stem cells, which have powerful anti-inflammatory and immune regulatory functions, inhibiting the cytokine storms. In addition, MSCs have a strong ability to repair tissue damage and reduce the risk of severe complications such as acute lung injury and ARDS, and hopefully, reduce the fatality rate in these patients. There are several clinical types of research completed for treating COVID-19 with MSCs, all reporting restoration of T cells and clinical safety. Here we discuss the clinical prospect and conclude the therapeutic effects and potential mechanism for MSCs in treating COVID-19.

Keywords: Mesenchymal stem cells, immune, regulate, repair, COVID-19, secretome.

« Previous Next »
Graphical Abstract

[1]
De Deyn MLZQ, Ng QX, Loke W, Yeo WS. A tale of two cities: A comparison of Hong Kong and Singapore’s early strategies for the Coronavirus Disease 2019 (COVID-19). J Infect 2020; 81(3): e51-2.
[http://dx.doi.org/10.1016/j.jinf.2020.06.058] [PMID: 32593657]
[2]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[3]
Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.16.20023903]
[4]
Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020; 95(6): E131-4.
[http://dx.doi.org/10.1002/ajh.25774] [PMID: 32129508]
[5]
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55(5): 105955.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105955] [PMID: 32234468]
[6]
Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep 2019; 15(2): 166-75.
[http://dx.doi.org/10.1007/s12015-018-9866-1] [PMID: 30623359]
[7]
Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19) induced pneumonia. Aging Dis 2020; 11(2): 462-4.
[http://dx.doi.org/10.14336/AD.2020.0301] [PMID: 32257554]
[8]
Liu S, Peng D, Qiu H, Yang K, Fu Z, Zou L. Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Res Ther 2020; 11(1): 169.
[http://dx.doi.org/10.1186/s13287-020-01678-8] [PMID: 32366290]
[9]
Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis 2020; 96: 431-9.
[http://dx.doi.org/10.1016/j.ijid.2020.05.040] [PMID: 32425638]
[10]
Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci 2015; 1351: 114-26.
[http://dx.doi.org/10.1111/nyas.12815] [PMID: 26152292]
[11]
Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe covid-19 infections: premises for the therapeutic use. Cells 2020; 9(4): 924.
[http://dx.doi.org/10.3390/cells9040924] [PMID: 32283815]
[12]
Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells 2019; 8(8): 784.
[http://dx.doi.org/10.3390/cells8080784] [PMID: 31357692]
[13]
Rajarshi K, Chatterjee A, Ray S. Combating covid-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst) 2020; 26: e00467.
[http://dx.doi.org/10.1016/j.btre.2020.e00467] [PMID: 32420049]
[14]
Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med 2020; 9(1): 28-38.
[http://dx.doi.org/10.1002/sctm.19-0205] [PMID: 31647191]
[15]
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105(4): 1815-22.
[http://dx.doi.org/10.1182/blood-2004-04-1559] [PMID: 15494428]
[16]
Khare D, Or R, Resnick I, Barkatz C, Almogi-Hazan O, Avni B. Mesenchymal stromal cell-derived exosomes affect mrna expression and function of b-lymphocytes. Front Immunol 2018; 9: 3053.
[http://dx.doi.org/10.3389/fimmu.2018.03053] [PMID: 30622539]
[17]
Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med 2017; 196(10): 1275-86.
[http://dx.doi.org/10.1164/rccm.201701-0170OC] [PMID: 28598224]
[18]
Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014; 15(11): 1009-16.
[http://dx.doi.org/10.1038/ni.3002] [PMID: 25329189]
[19]
Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Med Inflamm 2016; 2016: 2347938.
[http://dx.doi.org/10.1155/2016/2347938] [PMID: 27313398]
[20]
Deffune E, Prudenciatti A, Moroz A. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients. Med Hypotheses 2020; 14: 2109769.
[http://dx.doi.org/10.1016/j.mehy.2020.109769] [PMID: 32371362]
[21]
Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 2016; 7(1): 125.
[http://dx.doi.org/10.1186/s13287-016-0363-7] [PMID: 27581859]
[22]
Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med 2017; 6(6): 1445-51.
[http://dx.doi.org/10.1002/sctm.17-0051] [PMID: 28452204]
[23]
Crivelli B, Chlapanidas T, Perteghella S, et al. Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J Control Release 2017; 262: 104-17.
[PMID: 28736264]
[24]
Ji F, Li L, Li Z, Jin Y, Liu W. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem Cells Transl Med 2020; 9(7): 813-4.
[http://dx.doi.org/10.1002/sctm.20-0083] [PMID: 32320535]
[25]
Di Rocco G, Baldari S, Toietta G. Towards therapeutic delivery of extracellular vesicles: strategies for in vivo tracking and bio distribution analysis. Stem Cells Int 2016; 2016: 5029619.
[http://dx.doi.org/10.1155/2016/5029619] [PMID: 27994623]
[26]
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 2020; 29(12): 747-54.
[http://dx.doi.org/10.1089/scd.2020.0080] [PMID: 32380908]
[27]
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging Dis 2020; 11(2): 216-28.
[http://dx.doi.org/10.14336/AD.2020.0228] [PMID: 32257537]
[28]
Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 2020; 51: 00019.
[http://dx.doi.org/10.1016/j.medidd.2020.100019] [PMID: 32296777]
[29]
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for covid-19: present or future. Stem Cell Rev Rep 2020; 16(3): 427-33.
[http://dx.doi.org/10.1007/s12015-020-09973-w] [PMID: 32281052]

Rights & Permissions Print Cite
Article Metrics
50
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy